Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Axcella Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11309
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Axcella Health Inc (Axcella), formerly Pronutria Biosciences Inc is a developer of disease-specific amino acid profiles. The company’s lead clinical-stage candidates AXA are based on cell-specific sets of amino acids that regulate multiple biological pathways. Its amino acid therapies helps in treating orphan diseases in muscle, neurological, metabolic and liver settings, which include myotonic dystrophy, intractable epilepsy syndromes, pediatric nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, sarcopenia and other disease populations. Axcella conducts human signal seeking and confirming studies to understand the impact of various AXA candidates on human liver biology. The company uses a proprietary platform to identify the amino acid profile associated with a medical condition and de-risk the clinical development process. Axcella is headquartered in Cambridge, Massachusetts, the US.

Axcella Health Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Axcella Health Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Pronutria Raises USD39 Million in Series C Financing 10
Pronutria Raises USD28.3 Million in Venture Financing 11
Pronutria Raises US$12.3 Million In Series B Financing 12
Axcella Health (Pronutria Biosciences) Secures USD12.25 Million in Series B Funding Round 13
Pronutria Raises US$10.8 Million In Series A Financing 14
Partnerships 15
KineMed Enters into R&D Agreement with Pronutria Biosciences 15
Equity Offering 16
Pronutria Biosciences Raises USD42.5 Million in Equity Investment 16
Axcella Health Inc – Key Competitors 17
Axcella Health Inc – Key Employees 18
Axcella Health Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Oct 22, 2018: Axcella appoints Stephen Mitchener, PharmD, to senior vice president, chief business officer 20
Jun 27, 2018: Axcella Welcomes William D. Baird, and Cristina M. Rondinone to Board of Directors 21
May 31, 2018: Axcella Health Names Bill Hinshaw as President and Chief Executive Officer 23
Jan 03, 2018: Axcella Announces Appointment of David Epstein, Former CEO of Novartis Pharmaceuticals, as Chairman of its Board of Directors 24
Sep 14, 2017: Axcella Appoints Manu Chakravarthy, M.D., Ph.D., as Chief Medical Officer 25
Jun 14, 2017: Axcella Appoints Tony Tramontin, Ph.D., as Senior Vice President, Chief Scientific Officer 26
May 11, 2017: Axcella Announces the Appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., as Executive Vice President, Chief Strategy and Corporate Development Officer 27
Jan 03, 2017: Axcella Augments Leadership Team with the Appointment of Three Key Hires 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Axcella Health Inc, Pharmaceuticals & Healthcare, Key Facts 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pronutria Raises USD39 Million in Series C Financing 10
Pronutria Raises USD28.3 Million in Venture Financing 11
Pronutria Raises US$12.3 Million In Series B Financing 12
Axcella Health (Pronutria Biosciences) Secures USD12.25 Million in Series B Funding Round 13
Pronutria Raises US$10.8 Million In Series A Financing 14
KineMed Enters into R&D Agreement with Pronutria Biosciences 15
Pronutria Biosciences Raises USD42.5 Million in Equity Investment 16
Axcella Health Inc, Key Competitors 17
Axcella Health Inc, Key Employees 18

List of Figures
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kronos Worldwide Inc (KRO):企業の財務・戦略的SWOT分析
    Kronos Worldwide Inc (KRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析
    Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Northwest Biotherapeutics Inc (NWBO):製薬・医療:M&Aディール及び事業提携情報
    Summary Northwest Biotherapeutics Inc (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer. The company by utilizing its proprietary technology platform, DCVax, developed a robust pipeline of therapeutic product candidates. DCVax is …
  • Ambuja Cements Limited:企業の戦略・SWOT・財務分析
    Ambuja Cements Limited - Strategy, SWOT and Corporate Finance Report Summary Ambuja Cements Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Texwinca Holdings Limited:企業の戦略・SWOT・財務分析
    Texwinca Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Texwinca Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Corvel Corporation
    Corvel Corporation - Strategy, SWOT and Corporate Finance Report Summary Corvel Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Adani Enterprises Ltd (ADANIENT)
    Adani Enterprises Ltd (ADANIENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Aushon BioSystems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that offers biomarker measurement and analysis products. The company provides biomarker therapeutic areas in microarray printing technology. Its products include ciraplex assay, cirascan imaging and cirasoft analysis and cira servic …
  • Rhizen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析
    Summary Rhizen Pharmaceuticals SA (Rhizen Pharma), a subsidiary of Alembic Pharmaceuticals Ltd is a biopharmaceutical company that discovers and develops small molecule drugs. The company’s research products includes c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 ag …
  • DocCheck AG (AJ91):企業の財務・戦略的SWOT分析
    DocCheck AG (AJ91) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Marston’s PLC:企業の戦略・SWOT・財務情報
    Marston's PLC - Strategy, SWOT and Corporate Finance Report Summary Marston's PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Logibec Groupe Informatique Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Logibec Groupe Informatique Ltd (Logibec), a subsidiary of GI Partners LLC, is a technology company that develops, markets, implements and supports clinical and administrative information systems. The company offers administrative solutions include Espresso FMS and MMS, an integrated informa …
  • Linde AG (LIN)-エネルギー分野:企業M&A・提携分析
    Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. Linde offers a wide range of compressed and liquefied gases, and chemicals, and offers facili …
  • Suda Pharmaceuticals Ltd (SUD):企業の財務・戦略的SWOT分析
    Summary Suda Pharmaceuticals Ltd (Suda Pharmaceuticals), formerly Suda Ltd is a drug delivery company that offers oro-mucosal administration solutions. The company offers products such as SUD-001, SUD-002, SUD-003, SUD-004 and SUD-005, artimist, and zolpimist. Its artimist is a sub-lingual spray for …
  • Packaging Corporation of America (PKG):企業の財務・戦略的SWOT分析
    Packaging Corporation of America (PKG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • CCM Duopharma Biotech Bhd (CCMDBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary CCM Duopharma Biotech Bhd (CCMD), a subsidiary of Chemical Company of Malaysia Bhd, is a pharmaceutical company that develops, manufactures and markets generic drugs and branded pharmaceutical products. The company offers products in the form of tablets, capsules, syrup, oral antibiotic, cre …
  • Small Industries Development Bank of India:企業のM&A・事業提携・投資動向
    Small Industries Development Bank of India - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Small Industries Development Bank of India Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Mitsubishi Chemical Corp:企業の戦略的SWOT分析
    Mitsubishi Chemical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • PharmaCyte Biotech Inc (PMCB):企業の財務・戦略的SWOT分析
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • MEC Resources Ltd (MMR):企業の財務・戦略的SWOT分析
    MEC Resources Ltd (MMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆